EML4-ALK fusion

The gene fusion assay maker is the sixth member to join the consortium, which also includes Illumina and several pharmaceutical companies.

Pfizer's Xalkori yielded significantly longer progression-free survival than standard chemotherapy in the Phase III trial of first-line treatment of ALK-positive NSCLC.

Using NanoString's nCounter technology, researchers from Pfizer and Seoul National University have developed an ALK test they hope will be as accurate as the gold standard fluorescence in situ hybridization test for identifying patients who could benefit from Pfizer's Xa

New Releases

Premium

Response Genetics' ResponseDX: Lung

In PLOS this week: grey wolf population genomics, mutations associated with lung adenocarcinoma survival, and more.

An opinion piece at Bloomberg discusses China's stance on genomic research.

Genetic ancestry testing can affect a person's sense of identity, the New York Times Magazine writes.

Nebula Genomics is launching its genome sequencing service for free for people who provide certain information about themselves, the Boston Globe reports.